2023
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Nagaraj G, Vinayak S, Khaki A, Sun T, Kuderer N, Aboulafia D, Acoba J, Awosika J, Bakouny Z, Balmaceda N, Bao T, Bashir B, Berg S, Bilen M, Bindal P, Blau S, Bodin B, Borno H, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman L, Flora D, Friese C, Galsky M, Gonzalez C, Grivas P, Gupta S, Haynam M, Heilman H, Hershman D, Hwang C, Jani C, Jhawar S, Joshi M, Kaklamani V, Klein E, Knox N, Koshkin V, Kulkarni A, Kwon D, Labaki C, Lammers P, Lathrop K, Lewis M, Li X, de Lima Lopes G, Lyman G, Makower D, Mansoor A, Markham M, Mashru S, McKay R, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen R, Nonato T, O'Connor T, Panagiotou O, Park K, Patel J, Patel K, Peppercorn J, Polimera H, Puc M, Rao Y, Razavi P, Reid S, Riess J, Rivera D, Robson M, Rose S, Russ A, Schapira L, Shah P, Shanahan M, Shapiro L, Smits M, Stover D, Streckfuss M, Tachiki L, Thompson M, Tolaney S, Weissmann L, Wilson G, Wotman M, Wulff-Burchfield E, Mishra S, French B, Warner J, Lustberg M, Accordino M, Shah D. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study. ELife 2023, 12: e82618. PMID: 37846664, PMCID: PMC10637772, DOI: 10.7554/elife.82618.Peer-Reviewed Original ResearchConceptsCOVID-19 severityWorse COVID-19 outcomesCOVID-19 outcomesBreast cancerCause mortalityCohort studyAcute respiratory syndrome coronavirus 2 infectionCOVID-19Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionRegistry-based retrospective cohort studyHistory of BCIntensive care unit admissionNon-Hispanic white patientsSyndrome coronavirus 2 infectionWorse ECOG performance statusMultivariable ordinal logistic regression modelsCare unit admissionCoronavirus 2 infectionECOG performance statusRetrospective cohort studyPacific Islander patientsCoronavirus disease 2019American Cancer SocietyLogistic regression modelsResearch grant support
2013
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
Layman R, Ruppert A, Lynn M, Mrozek E, Ramaswamy B, Lustberg M, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut E, Shapiro C. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemotherapy And Pharmacology 2013, 71: 1183-1190. PMID: 23430121, PMCID: PMC3710373, DOI: 10.1007/s00280-013-2112-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBreast NeoplasmsCD4 Lymphocyte CountDose-Response Relationship, DrugErbB ReceptorsErlotinib HydrochlorideFemaleHumansLymphopeniaMiddle AgedNeoplasm MetastasisNitrogen Mustard CompoundsQuinazolinesSeverity of Illness IndexConceptsDose level 2Negative breast cancerCD4 countProlonged lymphopeniaBreast cancerMetastatic triple-negative breast cancerPurposeTriple-negative breast cancerEpidermal growth factor receptor expressionTriple-negative breast cancerEGFR tyrosine kinase inhibitorsDepressed CD4 countGrade 3/4 lymphopeniaDose level 1ECOG performance statusGrowth factor receptor expressionPhase I trialTyrosine kinase inhibitorsFactor receptor expressionHigh epidermal growth factor receptor (EGFR) expressionBendamustine combinationsConclusionsCombination therapyIntravenous bendamustineOral erlotinibPrior chemotherapyMetastatic disease
2010
Severe and Prolonged Lymphopenia Observed In Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer
Layman R, Ruppert A, Lynn M, Mrozek E, Ramaswamy B, Lustberg M, Susan O, Carothers S, Kraut E, Shapiro C. Severe and Prolonged Lymphopenia Observed In Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer. Blood 2010, 116: 1739. DOI: 10.1182/blood.v116.21.1739.1739.Peer-Reviewed Original ResearchTriple-negative breast cancerPneumocystis carinii pneumoniaDose level 2Metastatic triple-negative breast cancerNational Comprehensive Cancer NetworkDose level 1Serious adverse eventsNegative breast cancerStudy therapyProlonged lymphopeniaOpportunistic infectionsCombination therapyBreast cancerPhase I/II trialAdequate bone marrow functionEpidermal growth factor receptor expressionDepressed CD4 countGrade 3 infectionNon-hematologic toxicitiesOverall hematologic toxicityECOG performance statusGrowth factor receptor expressionWhole brain radiationAbsolute neutrophil countGrowth factor support